Physician profile
Keith R Harris
NPI 1922090224
$17,469.08
in general payments reported to CMS, 2019-2025
40 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,234 · 2020: $1,553 · 2021: $2,343 · 2022: $1,134 · 2023: $3,196 · 2024: $4,103 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,653 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,653.25 |
| Education | $552.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,097.63 | 2019-2025 | |
| Abbvie INC. | $2,524.59 | 2019-2025 | |
| Ucb, INC. | $1,183.91 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,171.98 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $1,145.50 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $1,140.66 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $869.42 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $824.45 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $718.19 | 2022-2024 | Vtama |
| Genzyme Corporation | $651.18 | 2019-2025 | |
| Pfizer INC. | $629.48 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $521.78 | 2019-2025 | Siliq, Targretin, Duobrii |
| Regeneron Healthcare Solutions, INC. | $447.05 | 2019-2025 | Libtayo, Dupixent |
| Galderma Laboratories, L.P. | $376.80 | 2019-2025 | Nemluvio, Aklief |
| Amgen INC. | $332.55 | 2019-2025 | Otezla, Otezla |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $267.68 | 2021-2023 | Opzelura |
| Leo Pharma INC. | $261.06 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Sanofi-Aventis U.S. LLC | $244.65 | 2019 | |
| Almirall LLC | $125.85 | 2022-2024 | Seysara |
| Organon LLC | $118.27 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $100.67 | 2019 | |
| Kerecis Limited | $86.66 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Sandoz INC. | $72.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.88 | 2023-2025 | Spevigo |
| Celgene Corporation | $60.21 | 2019 | |
| Journey Medical Corporation | $54.43 | 2020-2021 | |
| Biofrontera INC. | $46.47 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $45.78 | 2019-2020 | |
| Genentech USA, INC. | $35.04 | 2019-2023 | Erivedge |
| Aclaris Therapeutics, INC. | $29.72 | 2019 | |
| Vyne Pharmaceuticals INC. | $29.71 | 2020 | |
| Springworks Therapeutics, INC. | $29.03 | 2025 | Gomekli |
| Progenacare Global, LLC | $27.19 | 2024 | |
| Botanix Sb INC | $26.26 | 2025 | Sofdra |
| Biocon Biologics INC | $21.81 | 2024 | Hulio |
| Teva Pharmaceuticals USA, INC. | $20.54 | 2024 | Simlandi |
| Verrica Pharmaceuticals INC. | $19.60 | 2024 | Ycanth |
| Fresenius Kabi USA, LLC | $17.56 | 2023 | Idacio |
| Mylan Pharmaceuticals INC. | $12.98 | 2019 | |
| Merck Sharp & Dohme LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.